Korea Pfizer Pharmaceuticals said on the 14th that the respiratory syncytial virus (RSV) vaccine "Abrysvo" received approval from the Ministery of Food and Drug Safety.
Abrysvo is a bivalent vaccine that uses recombinant prefusion F proteins of RSV A and B as antigens.
When administered to pregnant people at 28–36 weeks of pregnancy, it can protect infants up to 6 months after birth, and people 60 and older and high‑risk groups ages 18–59 are also eligible.
In a phase 3 global clinical trial involving about 7,400 pregnant people, the risk of severe RSV lower respiratory tract disease in infants born to the Abrysvo group was up to 82.4% lower than in the placebo group. In a phase 3 trial involving about 37,000 people ages 60 and older, it reduced the risk of RSV lower respiratory tract disease by 88.9%.